Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): Results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi

References

• Armitage J O. Treatment of non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1023–1030
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C. [Aggressive lymphomas]. La Revue du praticien 1993; 43(13)1648–1653
   PubMedGoogle Scholar
• Vose J M, Armitage J O. What is the role of third generation regimens for initial therapy of non-Hodgkin's lymphomas?. Leuk Lymphoma 1993; 10(Suppl)61–64
   PubMedGoogle Scholar
• Child J A, Johnson S A, Rule S, Smith G M, Morgan G J, Johnson P W. FLUDAP: salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2000; 37(34)309–317
   PubMed Web of Science ®Google Scholar
• Seymour J F, Grigg A P, Szer J, Fox R M. Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma. Cancer 2002; 94(3)585–593
   PubMed Web of Science ®Google Scholar
• Reiser M, Josting A, Dias Wickramanayake P, Draube A, Scheid C, Tesch H. Dexa-BEAM is not effective in patients with relapsed or resistant aggressive high-grade non-Hodgkin's lymphoma. Leuk Lymphoma 1999; 33(34)305–312
   PubMed Web of Science ®Google Scholar
• Borghaei H, Millenson M, Schilder B, Alden M, Rogatko A, Wang H. Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma. Cancer 2004; 101(9)2034–2041
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Harousseau J L, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333(23)1540–1545
   PubMed Web of Science ®Google Scholar
• Webb M S, Saltman D L, Connors J M, Goldie J H. A literature review of single agent treatment of multiply relapsed aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2002; 43(5)975–982
   PubMed Web of Science ®Google Scholar
• Savage D G, Rule S A, Tighe M, Garrett T J, Oster M W, Lee R T. Gemcitabine for relapsed or resistant lymphoma. Ann Oncol 2000; 11(5)595–597
   PubMed Web of Science ®Google Scholar
• Sallah S, Wan J Y, Nguyen N P. Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol 2001; 113(1)185–187
   PubMed Web of Science ®Google Scholar
• Fossa A, Santoro A, Hiddemann W, Truemper L, Niederle N, Buksmaui S. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 1999; 17(12)3786–3792
   PubMed Web of Science ®Google Scholar
• Geffen D B, Man S. New drugs for the treatment of cancer, 1990–2001. Isr Med Assoc J 2002; 4(12)1124–1131
   PubMed Web of Science ®Google Scholar
• Balzarotti M, Santoro A, Tondini C, Fornier M, Bonadonna G. Activity of single agent vinorelbine in pretreated non-Hodgkin's lymphoma. Ann Oncol 1996; 7(9)970–972
   PubMed Web of Science ®Google Scholar
• Toh H C, Sun L, Koh C H, Aw S E. Vinorelbine induces apoptosis and caspase-3 (CPP32) expression in leukemia and lymphoma cells: a comparison with vincristine. Leuk Lymphoma 1998; 31(12)195–208
   PubMed Web of Science ®Google Scholar
• Sarris A H, Psyrri A, Hagemeister F, Romaguera J, McLaughlin P, Rodriguez M A. Infusional vinorelbine in relapsed or refractory lymphomas. Leuk Lymphoma 2000; 39(34)291–299
   PubMed Web of Science ®Google Scholar
• Moore M. Activity of gemcitabine in patients with advanced pancreatic carcinoma. A review. Cancer 1996; 78(3 Suppl)633–638
   PubMed Web of Science ®Google Scholar
• Kaufmann M, von Minckwitz G. Gemcitabine in ovarian cancer: an overview of safety and efficacy. Eur J Cancer 1997; 33(Suppl 1)S31–S33
   PubMed Web of Science ®Google Scholar
• Luftner D, Flath B, Akrivakis C, Grunewald B, Mergenthaler H G, Possinger K. Gemcitabine for palliative treatment in metastatic breast cancer. J Cancer Res Clin Oncol 1998; 124(10)527–531
   PubMed Web of Science ®Google Scholar
• Stadler W M, Kuzel T M, Raghavan D, Levine E, Vogelzang N J, Roth B, Dorr F A. Metastatic bladder cancer: advances in treatment. Eur J Cancer 1997; 33(Suppl 1)S23–S26
   PubMed Web of Science ®Google Scholar
• Murray N. New drugs for small-cell lung cancer. Oncology (Huntingt) 1997; 11(9 Suppl 9)38–42
   PubMedGoogle Scholar
• Carney D N. New agents in the management of advanced non-small cell lung cancer. Semin Oncol 1998; 25(4 Suppl 9)83–88
   PubMed Web of Science ®Google Scholar
• Green M R. Gemcitabine safety overview. Semin Oncol 1996; 23(5 Suppl 10)32–35
   PubMed Web of Science ®Google Scholar
• Abbruzzese J L. Phase I studies with the novel nucleoside analog gemcitabine. Semin Oncol 1996; 23(5 Suppl 10)25–31
   PubMed Web of Science ®Google Scholar
• Steward W P. Combination studies with gemcitabine in the treatment of non-small-cell lung cancer. Br J Cancer 1998; 78(Suppl 3)15–19
   PubMed Web of Science ®Google Scholar
• Fagbemi S O, Stadler W M. New chemotherapy regimens for advanced bladder cancer. Semin Urol Oncol 1998; 16(1)23–29
   PubMedGoogle Scholar
• Santoro A, Bredenfeld H, Devizzi L, Tesch H, Bonfante V, Viviani S. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol 2000; 18(13)2615–2619
   PubMed Web of Science ®Google Scholar
• Massoud M, Armand J P, Ribrag V. Procarbazine in haematology: an old drug with a new life. Eur J Cancer 2004; 40(13)1924–1927
   PubMed Web of Science ®Google Scholar
• Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348(24)2386–2395
   PubMed Web of Science ®Google Scholar
• Gobbi P G, Pieresca C, Federico M, Di Renzo N, Narni F, Iannitto E. MOPP/EBV/CAD hybrid chemotherapy with or without limited radiotherapy in advanced or unfavorably presenting Hodgkin's disease: a report from the Italian Lymphoma Study Group. J Clin Oncol 1993; 11(4)712–719
   PubMed Web of Science ®Google Scholar
• Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17(4)1244
   PubMed Web of Science ®Google Scholar
• Rodriguez-Monge E J, Cabanillas F. Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience. Hematol Oncol Clin North Am 1997; 11(5)937–947
   PubMed Web of Science ®Google Scholar
• Hanel M, Kroger N, Hoffknecht M M, Peters S O, Metzner B, Fiedler F. ASHAP—an effective salvage therapy for recurrent and refractory malignant lymphomas. Ann Hematol 2000; 79(6)304–311
   PubMed Web of Science ®Google Scholar
• Gutierrez M, Chabner B A, Pearson D, Steinberg S M, Jaffe E S, Cheson B D. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol 2000; 18(21)3633–3642
   PubMed Web of Science ®Google Scholar